Metformin synergistically enhances antiproliferative effects of cisplatin and etoposide in NCI-H460 human lung cancer cells;Metformina sinergicamente potencializa os efeitos antiproliferativos de cisplatina e etoposídeo em linhagem de células de câncer humano de pulmão NCI-H460

Jornal Brasileiro de Pneumologia

Volumn 39, Issue 6, 2013, Pages 644-649

  Teixeira, Sarah Fernandes ^a   Guimarães, Isabella dos Santos ^a   Madeira, Klesia Pirola ^a   Daltoé, Renata Dalmaschio ^a   Silva, Ian Victor ^a   Rangel, Leticia Batista Azevedo ^a  

^a FEDERAL UNIVERSITY OF ESPÍRITO SANTO   (Brazil)

Author keywords

Carcinoma; Combination; Drug therapy; Metformin; Non small cell lung

Indexed keywords

ANTIDIABETIC AGENT; ANTINEOPLASTIC AGENT; CISPLATIN; ETOPOSIDE; METFORMIN;

ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; DRUG COMBINATION; DRUG EFFECT; DRUG POTENTIATION; HUMAN; LARGE CELL CARCINOMA; METABOLISM; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, LARGE CELL; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CISPLATIN; DRUG COMBINATIONS; DRUG SYNERGISM; ETOPOSIDE; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN;

EID: 84892698492     PISSN: 18063713     EISSN: 18063756     Source Type: Journal    
DOI: 10.1590/S1806-37132013000600002     Document Type: Article

References (27)

1. Globocan 2008 [homepage on the Internet]. Lyon: International Agency for Research on Cancer.[updated 2008; cited 2013 May 26]. Globocan 2008 Fast Stats. Available from: http://globocan.iarc.fr/factsheets/populations/factsheet.asp?uno=900#BOTH
2. INCA [homepage on the Internet]. Rio de Janeiro: Ministério da Saúde. [updated 2012; cited 2013 May 5]. Tipo de câncer-Pulmão. Available from: http://www2.inca.gov.br/wps/wcm/connect/tiposdecancer/site/home/pulmao/definicao
3. SEER-Surveillance, Epidemiology, and End Results Program [homepage on the Internet]. Bethesda: National Cancer Institute. [updated 2009; cited 2013 Jun 30]. SEER Cancer Statistics Review, 1975-2007. Available from: http://seer.cancer.gov/csr/1975_2007/
4. IARC-International Agency for Research on Cancer [homepage on the Internet]. Lyon: International Agency for Research on Cancer. [updated 2004; cited 2013 Jul 01]. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. [Adobe Acrobat document, 344p.]. Available from: http://www.iarc.fr/en/publications/pdfs-online/pat-gen/bb10/BB10.pdf
5. NCBI-National Center for Biotechnology Information [homepage on the Internet]. Bethesda: National Center for Biotechnology Information. [updated 2011; cited 2013 Jul 05]. The Diagnosis and Treatment of Lung Cancer (Update). [Adobe Acrobat document, 198p.]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK99021/pdf/TOC.pdf
6. Ettinger DS, Bepler G, Bueno R, Chang A, Chang JY, Chirieac LR, et al. Non-small cell lung cancer clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2006;4(6):548-82. PMid:16813724
7. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006;58(3):621-81. Erratum in: Pharmacol Rev. 2007;59(1):124. http://dx.doi.org/10.1124/pr.58.3.10 PMid:16968952
8. IDF-International Diabetes Federation [homepage on the Internet]. Brussels: International Diabetes Federation. [updated 2005; cited 2013 Apr 02]. Global Guideline for Type 2 Diabetes. [Adobe Acrobat document, 82p.]. Available from: http://www.idf.org/webdata/docs/IDF%20GGT2D.pdf
9. Dilman VM. Age-associated elevation of hypothalamic, threshold to feedback control, and its role in development, ageing, and disease. Lancet. 1971;1(7711):1211-9. http://dx.doi.org/10.1016/S0140-6736(71)91721-1
10. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65(1-2):55-63. http://dx.doi.org/10.1016/0022-1759(83)90303-4
11. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27-55. http://dx.doi.org/10.1016/0065-2571(84)90007-4
12. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ. 2005;330(7503):1304-5. http://dx.doi.org/10.1136/bmj.38415.708634.F7 PMid:15849206 PMCid:PMC558205
13. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia. 2009;52(9):1766-77. http://dx.doi.org/10.1007/s00125-009-1440-6 PMid:19572116
14. Jiralerspong S, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C, Barnett CM, et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol. 2009;27(20):3297-302. http://dx.doi.org/10.1200/JCO.2009.19.6410 PMid:19487376 PMCid:PMC2736070
15. Larsson SC, Mantzoros CS, Wolk A. Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer. 2007;121(4):856-62. http://dx.doi.org/10.1002/ijc.22717 PMid:17397032
16. Tan BX, Yao WX, Ge J, Peng XC, Du XB, Zhang R, et al. Prognostic influence of metformin as first-line chemotherapy for advanced nonsmall cell lung cancer in patients with type 2 diabetes. Cancer. 2011;117(22):5103-11. http://dx.doi.org/10.1002/cncr.26151 PMid:21523768
17. Sterne J. Du Nouveau dans les antidiabétiques. La NN diméthylamino guanyl guanidine (N.N.D.G.). Maroc Med 1957;36:1295-6.
18. Iliopoulos D, Hirsch HA, Struhl K. Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. Cancer Res. 2011;71(9):3196-201. http://dx.doi.org/10.1158/0008-5472.CAN-10-3471 PMid:21415163 PMCid:PMC3085572
19. El-Mir MY, Nogueira V, Fontaine E, Avéret N, Rigoulet M, Leverve X. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem. 2000;275(1):223-8. http://dx.doi.org/10.1074/jbc.275.1.223 PMid:10617608
20. Hawley SA, Ross FA, Chevtzoff C, Green KA, Evans A, Fogarty S, et al. Use of cells expressing gamma subunit variants to identify diverse mechanisms of AMPK activation. Cell Metab. 2010;11(6):554-65. http://dx.doi.org/10.1016/j.cmet.2010.04.001 PMid:20519126 PMCid:PMC2935965
21. Hardie DG, Ross FA, Hawley SA. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol. 2012;13(4):251-62. http://dx.doi.org/10.1038/nrm3311 PMid:22436748
22. Inoki K, Zhu T, Guan KL. TSC2 mediates cellular energy response to control cell growth and survival. Cell. 2003;115(5):577-90. http://dx.doi.org/10.1016/S0092-8674(03)00929-2
23. Avizienyte E, Loukola A, Roth S, Hemminki A, Tarkkanen M, Salovaara R, et al. LKB1 somatic mutations in sporadic tumors. Am J Pathol. 1999;154(3):677-81. http://dx.doi.org/10.1016/S0002-9440(10)65314-X
24. Carretero J, Medina PP, Pio R, Montuenga LM, Sanchez-Cespedes M. Novel and natural knockout lung cancer cell lines for the LKB1/STK11 tumor suppressor gene. Oncogene. 2004;23(22):4037-40. http://dx.doi.org/10.1038/sj.onc.1207502 PMid:15021901
25. Shackelford DB, Abt E, Gerken L, Vasquez DS, Seki A, Leblanc M, et al. LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin. Cancer Cell. 2013;23(2):143-58. http://dx.doi.org/10.1016/j.ccr.2012.12.008 PMid:23352126
26. Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res. 2009;69(19):7507-11. Erratum in: Cancer Res. 2009;69(22):8832. http://dx.doi.org/10.1158/0008-5472.CAN-09-2994 PMid:19752085 PMCid:PMC2756324
27. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer. 2009;9(4):265-73. http://dx.doi.org/10.1038/nrc2620 PMid:19262571